AngioDynamics, Inc. (ANGO) stock news
The latest AngioDynamics, Inc. news and press releases. 0 news stories in the last 24 hours. ANGO stock report · Market news
Latest news
- Reasons to Hold AngioDynamics Stock in Your Portfolio for Now Zacks Investment Research, Nov 13, 5:21 PM UTC
ANGO's strong NanoKnife sales, expanding Med Tech portfolio and solid fiscal Q1 results support growth prospects, despite tariff and inflation pressures. - AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist Seeking Alpha, Oct 15, 5:27 PM UTC
AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction, yet face entrench... - AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer GuruFocus, Oct 14, 12:00 PM UTC
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste - ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y Zacks Investment Research, Oct 9, 4:00 PM UTC
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales. - AngioDynamics Stock Is Falling Thursday: What's Going On? Benzinga, Oct 8, 5:44 PM UTC
AngioDynamics Inc. (NASDAQ:ANGO) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results. - AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript Seeking Alpha, Oct 8, 3:23 PM UTC
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript - Why AngioDynamics Crashed Today The Motley Fool, Oct 8, 2:51 PM UTC
AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger. - AngioDynamics Q1 Earnings Call Highlights MarketBeat, Oct 8, 2:03 PM UTC
AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year outlook and announc... - AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates Zacks Investment Research, Oct 8, 12:22 PM UTC
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago. - AngioDynamics (NASDAQ:ANGO) Announces FY 2027 Earnings Guidance Defense World, Oct 8, 11:11 AM UTC
AngioDynamics (NASDAQ: ANGO - Get Free Report) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share guidance of -0.290-0.240 for the period, compared to the consensus EPS estimate... - 32,900 Shares in AngioDynamics, Inc. $ANGO Acquired by Canada Pension Plan Investment Board Defense World, Sep 3, 8:13 AM UTC
Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics, Inc. (NASDAQ: ANGO) during the undefined quarter, according to the company in its most recent disclosure with the Securities an...
Press releases
- AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire, Nov 6, 11:00 PM UTC
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatm... - AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE Business Wire, Oct 21, 12:30 PM UTC
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatm... - AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer Business Wire, Oct 14, 11:00 AM UTC
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatm... - AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Business Wire, Oct 8, 10:02 AM UTC
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatm... - AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer Business Wire, Oct 8, 10:00 AM UTC
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatm... - AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence Business Wire, Oct 2, 10:00 AM UTC
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving p... - AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 Business Wire, Sep 28, 8:30 PM UTC
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving p...
Headlines link to their publishers. Research data, not investment advice.